Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating senile ossification

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of lycium barbarum glycopeptide in preparation of a medicine for preventing or treating senile ossification. The experimental results show that the wolfberry glycopeptide can improve the posterior limb movement ability and the bone trabecula condition of old mice by increasing the femoral hardness, relieving the bone tissue calcium loss condition, improving the bone formation rate, promoting osteoblasts and inhibiting osteoclasts, so that the effect of treating bone aging is achieved. As a traditional Chinese medicinal material extraction product, the lycium barbarum glycopeptide can be effectively used for preventing and treating senile ossification, has the prospect of being developed into the medicine for preventing and treating senile ossification, provides more treatment choices for clinically preventing or treating senile ossification, and has important social benefits and economic values.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and particularly relates to the use of Lycium barbarum glycopeptide in preparing a medicine for preventing or treating senile ossification. Background Art

[0002] Senile osteoporosis is a chronic, progressive change in the skeleton during the aging process, characterized by a decrease in bone mass and destruction of bone tissue microstructure. It is the result of the combined effects of many physiological and pathological factors. Senile osteoporosis is often accompanied by serious complications such as osteoporotic fractures and intractable bone pain, and has become a serious problem in today's increasingly aging population. Modern medicine has no unified understanding of osteoporosis, and its treatment generally adopts drugs to improve osteoporosis, but the efficacy is uncertain, and there are many adverse reactions and high prices, which limit its application. Therefore, it is urgent to find a reliable treatment measure to treat senile osteoporosis.

[0003] Traditional Chinese Medicine (TCM) theory states that "the liver is the root of all life," "the liver controls essence, stores blood, and regulates movement," and "the kidneys store essence and regulate bone and marrow production." This suggests that bone metabolism is closely linked to liver and kidney function. Lycium barbarum (Lycium barbarum L.), a plant of the Solanaceae family, is the dried, mature fruit of the Ningxia wolfberry (Lycium barbarum L.). It enters the liver and kidney meridians, nourishing the liver and kidneys, improving essence and vision. The Compendium of Materia Medica states that "constant consumption of wolfberries strengthens bones, promotes lightness and prevents aging, and improves resistance to cold and heat."

[0004] Lycium barbarum glycopeptide (LbGp) is a glycoconjugate considered the most promising monomeric component of the wolfberry fruit. It comprises LbGp1 (88 kDa), LbGp2 (68.2 kDa), LbGp3 (92.5 kDa), LbGp4 (214.8 kDa), and LbGp5 (23.7 kDa). It is primarily composed of sugar chains, covalently bound to the polypeptide, with a molecular weight of 88 kDa. Its monosaccharide composition is arabinose (Ara), galactose (Gal), and glucose (Glc), with a molar ratio of 2.5:1.0:1.0. It contains 30% protein, and the linkage between the sugar moieties and the core protein backbone is O-linked. It also contains 18 other naturally occurring amino acids, ensuring quantitative and reproducible experimental results. Studies have shown that LbGp has the potential to lower blood sugar and lipids, reduce depression and anxiety, and prevent the onset and progression of acute colitis. However, so far there has been no relevant report on the preventive or therapeutic effects of Lycium barbarum glycopeptide on senile ossification.

[0005] The senescence accelerated mouse prone 6 (SAMP6) strain is a model mouse bred by inbreeding AKR / J mice. It has characteristics such as widespread osteopenia, bone tissue microarchitecture destruction, increased bone brittleness, low peak bone density, and low peak bone mass. These characteristics are similar to human osteoporosis and bone aging, making it an ideal model for studying senile bone aging. Therefore, the present invention treats 4.5-month-old SAMP6 mice with different doses of Lycium barbarum glycopeptide to study the therapeutic effects of Lycium barbarum glycopeptide on improving bone metabolism and bone aging. Based on this, a new use of the natural product Lycium barbarum glycopeptide in preventing or treating senile ossification has been discovered for the first time. Summary of the Invention

[0006] The purpose of the present invention is to solve the problem of insufficient clinically available drugs for the prevention or treatment of senile ossification with high efficacy, low toxicity and low price, to achieve in-depth development and utilization of natural products using modern pharmaceutical research methods, and to provide the use of Lycium barbarum glycopeptide in the preparation of drugs for the prevention or treatment of senile ossification in combination with a large number of pharmacodynamic experimental studies.

[0007] In order to achieve the purpose of the present invention, the present invention adopts the following technical solutions:

[0008] The present invention provides the use of Lycium barbarum glycopeptide in preparing a medicine for preventing or treating senile ossification.

[0009] Preferably, the present invention provides the use of Lycium barbarum glycopeptide as the sole active ingredient in the preparation of a drug for preventing or treating senile ossification.

[0010] As an option, in the above application, the senile bone aging is senile osteoporosis.

[0011] As an optional method, in the above application, the Lycium barbarum glycopeptide increases femoral hardness, alleviates calcium loss in bone tissue, and improves bone formation rate.

[0012] As an optional method, in the above application, the Lycium barbarum glycopeptide improves bone metabolism and promotes osteoblast formation.

[0013] As an optional method, in the above application, the preparation method of the wolfberry glycopeptide mainly includes the steps of washing, soaking, crushing and beating, extraction, double-pass beating, two-stage separation, membrane separation, single-effect concentration, and freeze-drying. In particular, the wolfberry seeds are separated in the double-pass beating step, the wolfberry pulp is separated in the two-stage centrifugation step, and the oligosaccharides are separated in the membrane separation step, and the final product obtained is the wolfberry glycopeptide.

[0014] As an optional manner, in the above application, the Lycium barbarum glycopeptide comprises one or more of the following: LbGp1, LbGp2, LbGp3, LbGp4 or LbGp5.

[0015] Among them: the protein content in LbGp1 is 28.87%, the protein content in LbGp2 is 9.25%, the protein content in LbGp3 is 5.19%, the protein content in LbGp4 is 10.75% and the protein content in LbGp5 is 59.87%.

[0016] As an optional method, in the above application, the Lycium barbarum glycopeptide contains LbGp1, LbGp2, LbGp3, LbGp4 and LbGp5, wherein the mass ratio of LbGp1, LbGp2, LbGp3, LbGp4 and LbGp5 is (0.01-0.02): (0.005-0.01): (0.01-0.02): (0.02-0.03): (0.01-0.02).

[0017] Preferably, in the Lycium barbarum glycopeptide, the mass ratio of LbGp1, LbGp2, LbGp3, LbGp4 and LbGp5 is 0.018:0.0077:0.018:0.029:0.014.

[0018] As an optional mode, in the above use, the medicine comprises Lycium barbarum glycopeptide and a pharmaceutically acceptable carrier.

[0019] As an optional mode, in the above use, the dosage form of the drug is tablets, pills, oral liquid, capsules, syrups, drop pills, granules, injections, powder injections or suppositories.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The present invention combines my country's advantages in natural product research and has discovered for the first time a new use for the natural product Lycium barbarum glycopeptide in preventing or treating senile ossification. Lycium barbarum glycopeptide can improve the hind limb motor ability and trabecular bone condition of elderly mice by increasing femoral hardness, alleviating calcium loss in bone tissue, increasing bone formation rate, promoting osteoblasts and inhibiting osteoclasts, thereby playing a role in treating bone aging. As a product extracted from traditional Chinese medicinal materials, Lycium barbarum glycopeptide can be effectively used in the prevention and treatment of senile ossification and has the prospect of being developed into a drug for the prevention and treatment of senile ossification. It provides more treatment options for the clinical prevention or treatment of senile ossification and has important social benefits and economic value. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:

[0023] Figure 1 : The time taken by mice in each group to complete climbing the pole (24 days after administration). * It means that the results of this group are statistically different from those of the control group. * P<0.05, ** P<0.01, *** P < 0.001; # It means that the results of this group are statistically different from those of the model group. # P<0.05, ## P<0.01, ### P < 0.001. Same below.

[0024] Figure 2 : Three-point bending test: maximum load.

[0025] Figure 3 : HE staining of femurs of mice in each group.

[0026] Figure 4 : Femora of mice in each group were stained with methylene blue-acid fuchsin.

[0027] Figure 5 : Trap staining of femurs of mice in each group.

[0028] Figure 6 : Von Kossa staining of femurs of mice in each group (100x).

[0029] Figure 7 : Micro CT scans of femurs of mice in each group.

[0030] Figure 8 : Parameters of femoral trabecular bone in each group of mice.

[0031] Figure 9 : Bone formation rate of mice in each group. DETAILED DESCRIPTION

[0032] The present inventors used modern pharmaceutical research methods to deeply develop and utilize natural products. Through extensive screening, they discovered for the first time that Lycium barbarum glycopeptide can prevent or treat senile ossification. Based on this, they completed the present invention.

[0033] As used herein, the dosage form of the pharmaceutical preparation of the present invention is a tablet, capsule, granule, oral solution or injection. Preferably, the dosage form of the present invention is a tablet or capsule.

[0034] As used herein, the "pharmaceutically acceptable carrier" of the present invention refers to a conventional drug carrier in the field of pharmaceutical preparations, selected from one or more of fillers, binders, disintegrants, lubricants, suspending agents, wetting agents, pigments, flavoring agents, solvents, and surfactants.

[0035] The fillers of the present invention include but are not limited to starch, microcrystalline cellulose, sucrose, dextrin, lactose, powdered sugar, glucose, etc.; the lubricants include but are not limited to magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, poloxamer, etc.; the binders include but are not limited to water, ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidone, etc.; the disintegrants include but are not limited to starch effervescent mixtures, i.e., sodium bicarbonate and citric acid, tartaric acid, low-substituted hydroxypropyl cellulose, etc.; the suspending agents include but are not limited to polysaccharides such as acacia gum, agar, alginic acid, cellulose ether, and carboxymethyl chitosan, etc.; the solvents include but are not limited to water, balanced salt solutions, etc.

[0036] Preferably, the drug of the present invention can be prepared into various solid oral preparations, liquid oral preparations, etc. Pharmaceutically acceptable oral solid preparations include: ordinary tablets, dispersible tablets, enteric-coated tablets, granules, capsules, dripping pills, powders, etc., and oral liquid preparations include oral liquids, emulsions, etc.

[0037] In addition, the drug of the present invention can also be prepared into an injection, including a water injection or a freeze-dried powder injection.

[0038] The above-mentioned various dosage forms can be prepared according to conventional processes in the field of pharmaceutical preparations.

[0039] As used herein, the "Lycium Barbarum Glycopeptide (LbGp)" powder used in the present invention is provided by Ningxia Tianren Lycium Barbarum Biotechnology Co., Ltd.

[0040] The preparation of the Lycium barbarum glycopeptide of the present invention involves extracting and isolating an aqueous extract of Lycium barbarum through pure physical centrifugation, membrane filtration purification, and vacuum freeze-drying to obtain a glycoconjugate of a polysaccharide covalently bound to a peptide chain. The glycoconjugate comprises LbGp1, LbGp2, LbGp3, LbGp4, and LbGp5. The protein content of LbGp1 is 28.87%, that of LbGp2 is 9.25%, that of LbGp3 is 5.19%, that of LbGp4 is 10.75%, and that of LbGp5 is 59.87%. The mass ratio of LbGp1, LbGp2, LbGp3, LbGp4, and LbGp5 in the Lycium barbarum glycopeptide is 0.018:0.0077:0.018:0.029:0.014.

[0041] In the medical uses described above, the administration time, number of administrations, and frequency of administration of "Lycium barbarum Glycopeptide" and other active ingredients need to be determined based on the specific diagnosis of the disease, which is within the technical scope of those skilled in the art. For example, if a treatment plan for mice is applied to humans, the effective dose of all drugs for humans can be converted based on the effective dose of the drug for mice, which is also easy for those skilled in the art to achieve.

[0042] In order to better understand the essence of the present invention, the following specific embodiments use pharmacodynamic experiments and their results to further illustrate the new use of Lycium barbarum glycopeptide in the pharmaceutical field for preventing or treating senile ossification.

[0043] The present invention will be further described below with reference to specific embodiments. It should be understood that the specific embodiments described herein are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0044] If no specific techniques or conditions are specified in the examples, the experiments were carried out according to the techniques or conditions described in the literature in the field or according to the product instructions. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0045] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0046] Example:

[0047] 1. Preparation method of Lycium barbarum glycopeptide

[0048] The preparation process for Lycium barbarum glycopeptide involves the following steps: raw material (dried wolfberries) - washing - soaking - crushing - extraction - filtration - concentration - freeze-drying - finished product. The main steps are as follows: After harvesting, the wolfberries are sun-dried, washed, and chopped. Ether and acetone are then used to extract the fat-soluble and partially water-soluble pigments from the berries. The berries are then soaked in neutral water. After soaking, the liquid is filtered and centrifuged to extract the supernatant. The supernatant is precipitated with anhydrous ethanol, the precipitate is dissolved in water, and the protein is released using a mixture of chloroform and n-butanol. After multiple dialysis and centrifugation to remove the precipitate, the supernatant is freeze-dried to obtain LBP. The extracted crude polysaccharide LBP is then purified again. First, LBP is subjected to column chromatography using DEAE-Cellulose and eluted with 0.05 mol / L NaHCO3 solution to obtain LBP-1. Next, LBP-1 needs to be dialyzed, desalted, and concentrated, and then subjected to column chromatography using Sephadex G100, followed by elution with 0.10 M NaCl solution. The eluted solution is freeze-dried to obtain Lycium barbarum glycopeptide (LbGp).

[0049] 2. Experimental Materials

[0050] SAMR1 mice, senescence-accelerated mice SAMP6 (purchased from Peking University Health Science Center, SCXK (Beijing) 2022-0009); Lycium barbarum glycopeptide powder (Ningxia Tianren Lycium barbarum Biotechnology Co., Ltd., 20231202); hematoxylin and eosin staining kit (G1120), tartrate-resistant acid phosphatase staining kit (G1492), methylene blue-acid fuchsin kit (R23038); calcein (S19167), tetracycline (S17051), etc.

[0051] 3. Experimental Methods

[0052] 3.1 Animal experiments

[0053] Sixteen four-and-a-half-month-old male SAMP6 mice were randomly divided into four groups (accelerated aging model group, low-dose group, medium-dose group, and high-dose group), with four mice in each group. Four four-and-a-half-month-old male SAMR1 mice served as the control group. Before the experiment, the mice were housed in an SPF laboratory for one week with an ambient temperature of 25°C and a 12-h light-dark cycle. They had free access to standard mouse chow and water. All animal procedures were carried out in strict accordance with the relevant international guidelines for the use of experimental animals. The low-, medium-, and high-dose groups were gavage-administered 10 mg / kg, 20 mg / kg, and 40 mg / kg of Lycium barbarum glycopeptide, respectively, and the remaining groups were gavage-administered with the same volume of normal saline, with a dosing volume of 0.1 mL / 10 g, for 28 days. During the intervention period, the mice were weighed and gavage-administered daily, and a behavioral experiment, a pole climbing test, was performed every two days. One hour after the last dose, the mice in each group were anesthetized, and serum and femoral tissue were isolated for subsequent experiments.

[0054] 3.2 Behavioral experiment: Pole climbing experiment

[0055] A wooden pole with a diameter of 1 cm and a length of 80 cm was used, and the surface was wrapped with medical tape to increase the surface friction of the pole to prevent the mice from slipping; the pole climbing experiment was performed every two days, repeated three times for each mouse, and the time it took for the mouse to climb from the top of the pole to the bottom was recorded.

[0056] 3.3 Biomechanics: Three-point bending test

[0057] The femur was fixed on an Acumen3 biomechanical testing instrument with a span of 25 mm and a loading speed of 2 mm / min until the femur broke. The maximum load on the femur was calculated and the femoral strength was evaluated.

[0058] 3.4 Histopathological examination

[0059] 3.4.1 Mouse femur decalcified embedded sections

[0060] 3.4.2 Non-decalcified embedded hard tissue sections of mouse femur

[0061] 3.4.3 HE staining of mouse femur

[0062] 3.4.4 Methylene blue-acid fuchsin staining of mouse femur

[0063] 3.4.5 Tartrate-resistant acid phosphatase staining of mouse femur

[0064] 3.4.6 Von Kossa staining of mouse femur

[0065] 3.5 Bone imaging examination

[0066] 3.5.1 Micro CT 3D Reconstruction

[0067] The sample was placed in a sample tube and scanned using a μCT100 micro-CT to generate TIF image data.

[0068] 3.5.2 Calculation of trabecular bone parameters

[0069] Analyze the image data, calculate the proportion of trabecular bone, generate a test analysis report, and make a comparison.

[0070] 3.6 Assessment of bone formation rate

[0071] During the animal experiment, bone tissue was labeled with fluorescein by intraperitoneal injection of tetracycline 9 and 10 days before the end of the experiment, and by intraperitoneal injection of calcein 3 days before the end of the experiment. Femoral hard tissue sections were then observed under a fluorescence microscope for yellow and green fluorescence. The distance between the two fluorescence lines was compared between groups to assess bone formation rate.

[0072] 3.7 Statistical methods

[0073] All data were processed using SPSS 16.0 statistical software. Measurement data were expressed as mean ± standard deviation. One-way analysis of variance (ANOVA) was used for comparisons between multiple groups. When the variances between groups were equal, pairwise comparisons between groups were performed using the LSD test. When the variances were unequal, pairwise comparisons between groups were performed using the Dunnet's T3 test. P < 0.05 indicated statistical significance.

[0074] 4. Experimental Results

[0075] 4.1 Animal behavior experiment: pole climbing experiment

[0076] The results of the pole climbing experiment are as follows Figure 1 The results showed that the time required for SAMP6-induced rapid aging mice to climb the pole was significantly prolonged; from the 10th day onwards, the climbing time of mice in the high and medium dose groups was significantly shortened, while the climbing time of mice in the low dose group did not change significantly.

[0077] 4.2 Biomechanics: Three-point bending test

[0078] The results of the three-point bending test to detect the maximum load of the femur of each group of mice are as follows Figure 2 The experimental results showed that the maximum load of the femur of SAMP6 osteoporotic aging mice was significantly lower than that of the control mice. After administration of different doses of Lycium barbarum glycopeptide, the maximum load of the femur was significantly increased, indicating that Lycium barbarum glycopeptide can improve the femoral strength of SAMP6 aging mice.

[0079] 4.3 Histopathological Detection: Mouse Femur Staining

[0080] 4.3.1 HE staining of mouse femur

[0081] HE staining results of paraffin-embedded sections of mice in each group are shown in Figure 2. Figure 3 As shown in the figure. The results showed that in the femurs of the control group and the Lycium barbarum glycopeptide group, densely arranged new trabeculae (red arrows) were visible near the epiphyseal line. The trabeculae were covered with basophilic dye-stained osteoblasts (blue arrows), and the cortical and cancellous bone structures were intact. In the model group, no obvious trabeculae were found near the epiphyseal line, and the bone tissue was vacuolated (green arrows) and had an incomplete morphology. These results indicate that Lycium barbarum glycopeptide can improve femoral bone metabolism in SAMP6 mice and promote osteoblastogenesis.

[0082] 4.3.2 Mouse femoral osteoblast staining

[0083] The results of methylene blue-acid fuchsin staining of mice in each group are as follows Figure 4 As shown. Methylene blue-acid fuchsin staining solution can clearly show osteoblasts, new bone and osteoid: dark blue is osteoblast nuclei; light blue is cell matrix; dark red is new bone tissue. The results showed that: in the control group, some new bone tissue (blue arrow) and a large number of dark blue osteoblast nuclei (red arrow) were visible; in the model group, there was almost no new bone tissue (blue arrow) and few dark blue osteoblast nuclei; in the high-dose group, a large area of new bone tissue was visible, and there were dense osteoblast nuclei. The results indicate that Lycium barbarum glycopeptide can promote osteoblasts in the femur of rapidly aging osteoporotic mice, thereby improving bone metabolism.

[0084] 4.3.3 Mouse femoral osteoclast staining

[0085] The results of tartrate-resistant acid phosphatase staining of mice in each group are as follows Figure 5As shown. Tartrate-resistant acid phosphatase (trap) staining solution can show osteoclasts in tissues: the osteoclast cytoplasm is stained purple, and the nucleus is stained dark blue by hematoxylin. The results showed that a large area was stained purple-red (red arrow) on the slices of the model group, while the purple-red area was smaller on the slices of the control group and the high-dose group, indicating that Lycium barbarum glycopeptide can significantly inhibit osteoclasts, thereby improving bone metabolism. 4.3.4 Von Kossa staining of mouse femoral hard tissue slices

[0086] The results of Von Kossa staining of hard tissue sections of mice in each group are as follows Figure 6 In hard tissue sections, since no decalcification is performed, the calcium in the bone tissue is retained, allowing observation of calcium metabolism within the femur and differentiation between mineralized and non-mineralized bone. In Von Kossa staining, calcium ions in the tissue are replaced with anions, meaning that the black areas observed under the microscope represent areas of calcium distribution.

[0087] This hard tissue sectioning was performed using a transverse cutting method to obtain a cross-section of the femoral tissue. The periphery of the cross-section is the bone tissue, and the interior is the bone marrow cavity. Normally, calcium is distributed in large quantities in the peripheral bone tissue. When osteoporosis occurs, calcium is lost from the bone tissue and flows to the bone marrow cavity, blood vessels, and other parts, where calcium is deposited. Observation of the sections showed that the control group had a large number of black areas distributed in the peripheral parts (red arrows); the model group had fewer and thinner black areas in the periphery, and a large number of black areas were deposited in the central bone marrow cavity (orange arrows); the Lycium barbarum glycopeptide-treated group showed a dose-dependent thickening of the peripheral black area (red arrows) and a reduction in the internal black area. In summary, Lycium barbarum glycopeptide intervention can improve the phenomenon of calcium loss in osteoporotic bone tissue in SAMP6 mice, thereby alleviating bone aging.

[0088] 4.4 Imaging Detection

[0089] 4.4.1 Micro CT 3D reconstruction of mouse femur

[0090] The results of Micro CT three-dimensional reconstruction of mouse femur were obtained by scanning. Figure 7 As shown in the figure, microCT 3D reconstructions of the femurs of each mouse were obtained by scanning. It can be seen that the femoral structure of the model group and the medium-dose mice was incomplete and had multiple fractures, while the condition of the high-dose group mice improved. This shows that Lycium barbarum glycopeptide can improve the femoral trabeculae in mice with rapid aging and osteoporosis.

[0091] 4.4.2 Mouse femoral trabecular bone parameters

[0092] The trabecular bone parameters of each group of mice were calculated and the results were as follows: Figure 8 A- Figure 8As shown in Figure D. The results show that in the model group, the number of trabeculae decreased, the porosity of trabeculae increased, the structural model index (SMI) increased (the structural model index (SMI) is an indicator used to describe the degree of plate-like and rod-like trabeculae: when osteoporosis occurs, trabeculae change from plate-like to rod-like, and the SMI value increases). The ratio of bone volume to bone surface area increased. All of these improvements were seen after intervention with the high-dose Lycium barbarum glycopeptide group, but there was no significant difference in bone structural anisotropy. This indicates that Lycium barbarum glycopeptide can improve bone aging and trabecular growth in SAMP6 mice.

[0093] 4.5 Bone formation rate in mice

[0094] The femoral fluorescence results of mice in each group were as follows Figure 9 The results showed that the gap between the two fluorescence channels of the model group mice narrowed, while the fluorescence gap of the dose group mice thickened (red arrow), indicating that high-dose Lycium barbarum glycopeptide can increase the bone formation rate and improve bone metabolism in elderly mice.

[0095] 5. Experimental Conclusion

[0096] Lycium barbarum glycopeptide can improve the hind limb motor ability and trabecular condition of elderly mice by increasing femoral hardness, alleviating calcium loss in bone tissue, increasing bone formation rate, promoting osteoblasts and inhibiting osteoclasts, thereby playing a role in treating bone aging.

[0097] Obviously, those skilled in the art may make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if such changes and modifications fall within the scope of the claims and their equivalents, the present invention is intended to include such changes and modifications.

Claims

1. Application of Lycium barbarum glycopeptide in the preparation of drugs for preventing or treating senile ossification.

2. The use according to claim 1, characterized in that: The senile bone aging is senile osteoporosis.

3. The use according to claim 1, characterized in that: The wolfberry glycopeptide increases femoral hardness, alleviates calcium loss in bone tissue, and improves bone formation rate.

4. The use according to claim 1, characterized in that: The wolfberry glycopeptide improves bone metabolism and promotes osteoblast formation.

5. The use according to claim 1, characterized in that: The Lycium barbarum glycopeptide comprises one or more of the following: LbGp1, LbGp2, LbGp3, LbGp4 or LbGp5.

6. The use according to claim 5, characterized in that: The Lycium barbarum glycopeptide comprises LbGp1, LbGp2, LbGp3, LbGp4 and LbGp5, wherein the mass ratio of LbGp1, LbGp2, LbGp3, LbGp4 and LbGp5 is (0.01-0.02): (0.005-0.01): (0.01-0.02): (0.02-0.03): (0.01-0.02).

7. The use according to any one of claims 1 to 6, characterized in that: The medicine comprises wolfberry glycopeptide and a pharmaceutically acceptable carrier.

8. The use according to claim 7, characterized in that: The dosage form of the medicine is tablet, pill, oral liquid, capsule, syrup, dripping pill, granule, injection, powder injection or suppository.

Images